达格列净联合沙库巴曲缬沙坦改善非2型糖尿病慢性心力衰竭患者心功能的随机对照试验  

Randomized controlled trial of dapagliflozin combined with shakubatravalsartan in improving cardiac function in patients with non-type 2 diabetic chronic heart failure

作　　者：李好 朱文书 梅廷方[1] 刘安全[1] LI Hao;ZHU Wen-shu;MEI Ting-fang(Bengbu First People's Hospital,Bengbu 233000,China)

机构地区：[1]蚌埠市第一人民医院,安徽蚌埠233000

出　　处：《中国处方药》2024年第6期90-93,共4页Journal of China Prescription Drug

基　　金：2021年度蚌埠市第一人民医院科研计划(bb1yky2021003)。

摘　　要：目的探讨达格列净联合沙库巴曲缬沙坦治疗非2型糖尿病慢性心力衰竭(CHF)患者的临床疗效。方法选取2022年2月~2023年5月在蚌埠市第一人民医院心血管内科收住的慢性心力衰竭患者95例,随机将患者分为观察组47例和对照组48例,对照组予以沙库巴曲缬沙坦治疗,观察组在对照组基础上加用达格列净治疗,两组均治疗3个月,比较两组患者治疗前后的心功能、NT-proBNP、左房内径、血尿酸、空腹血糖变化及不良反应发生率等情况。结果治疗前两组患者年龄、性别、体重指数、心率、EF值、NT-proBNP、左房内径、空腹血糖、甘油三酯、胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、肌酐比较,差异无统计学意义(P>0.05)。治疗3个月后,观察组血尿酸、NT-proBNP、左房内径较对照组下降,差异有统计学意义(P<0.05);左室EF值较对照组升高,差异有统计学意义(P<0.05);两组空腹血糖变化差异无统计学意义(P>0.05)。观察组不良反应总发生率(6.38%)略高于对照组(6.25%),差异无统计学意义(P>0.05)。结论达格列净可有效改善非2型糖尿病慢性心力衰竭患者的心功能,安全有效,不良反应少。Objective To explore the clinical efficacy of dapagliflozin combined with shakubatrivasartan in the treatment of chronic heart failure(CHF)in patients with non-type 2 diabetes mellitus.Methods 95 patients with chronic heart failure admitted to the Cardiovascular Department of Bengbu First People's Hospital from February 2022 to May 2023 were randomly divided into observation group(47 cases)and control group(48 cases).The control group was treated with shakubatravalsartan,and the observation group was treated with dapagliflozin on the basis of the control group.The two groups were treated for 3 months.The cardiac function,NT-proBNP,left atrial diameter,serum uric acid and fasting glucose changes before and after treatment and the incidence of adverse reactions were compared between the two groups.Results There was no significant difference in age,sex,body mass index,heart rate,EF value,NT-proBNP,left atrial diameter,fasting blood glucose,triglyceride,cholesterol,HDL-C,LDL-C and creatinine between the two groups before treatment(P>0.05).After 3 months of treatment,the serum uric acid,NT-proBNP and left atrial diameter in the observation group were lower than those in the control group,with statistical significance(P<0.05);he left ventricular EF value was higher than that of the control group,and the difference was statistically significant(P<0.05);there was no significant difference in fasting blood glucose changes between the two groups(P>0.05).The total incidence of adverse reactions in the observation group(6.38%)was slightly higher than that in the control group(6.25%),with no statistical significance(P>0.05).Conclusion Dapagliflozin can effectively improve the cardiac function of chronic heart failure patients with non-type 2 diabetes mellitus,which is safe and effective with few adverse reactions.

关 键 词：达格列净 沙库巴曲缬沙坦 慢性心力衰竭 非2型糖尿病 

分 类 号：R587.2[医药卫生—内分泌] R541.6[医药卫生—内科学]